Navigation Links
Gene Therapy - Technologies, Markets and Companies
Date:11/30/2011

-induced pulmonary fibrosis 173

Pulmonary complications of a1-antitrypsin deficiency 173

Gene therapy for asthma 174

Gene therapy for adult respiratory distress syndrome 175

Gene therapy for lung injury 175

Gene therapy for bronchopulmonary dysplasia 175

Concluding remarks about gene therapy of lungs 176

Companies involved in pulmonary gene therapy 176

Skin and soft tissue disorders 177

Gene transfer to the skin 177

Electroporation for transdermal delivery of plasmid DNA 177

Electroporation for transdermal delivery of DNA vaccines 178

Liposomes for transdermal gene delivery 178

Ultrasound and topical gene therapy 178

Gene therapy in skin disorders 178

Gene therapy of hair loss 179

Gene therapy for xeroderma pigmentosa 179

Gene therapy for lamellar ichthyosis 179

Gene therapy for epidermolysis bullosa 180

Gene transfer techniques for wound healing 180

Urogenital disorders 181

Gene therapy for urinary tract dysfunction 181

Gene therapy for erectile dysfunction 181

NOS gene transfer for erectile dysfunction 181

Clinical trial of hMaxi-K Gene transfer in erectile dysfunction 182

Gene therapy for erectile dysfunction due to nerve injury 182

Concluding remarks on gene therapy for erectile dysfunction 182

Veterinary gene therapy 183

Gene therapy for mucopolysaccharidosis VII in dogs 183

Gene therapy to increase disease resistance 183

Gene therapy for infections 184

Gene therapy for chronic anemia 184

Gene therapy for endocrine disorders 185

Gene therapy for arthritis 185

Cancer gene therapy 185

Brain tumors in cats and dogs 185

Breast cancer in dogs 186

Canine hemangiosarcoma 187

Canine melanoma 187

Canine soft tissue sarcoma 187

Melanoma in horses 188

4. Gene Therapy of Genetic Disorders 18
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
2. Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
3. Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
4. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
5. New Findings Reported by TJ Gan and Authors from Duke Anesthesiology Demonstrate Efficacy of Cheetah Medicals NICOM® Bioreactance® Technology to Guide Goal Directed Intraoperative Therapy
6. Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
7. KGI Professor Awarded Patent for Stem-Cell Therapy Aiding Heart-attack Patients
8. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
9. EGEN, Inc. Collaborates With Nanotechnology Characterization Laboratory on Brain Cancer Therapy
10. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
11. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., ... has filed a Clinical Trial Application (CTA) with the ... Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical ... Anatabine Citrate. Contingent on the Company receiving ... Phase I trial to assess the safety, tolerability and ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... DIEGO , Dec. 22, 2014 GenomeDx ... the Decipher Prostate Cancer Classifier, a genomic test for ... in node-negative, high-risk men managed by radical prostatectomy without ... radical prostatectomy is relatively uncommon, using tumor genomics to ... of metastatic disease is an important advance. The study ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... BALTIMORE, June 14, 2011 Arcion Therapeutics , ... therapies for chronic pain, today announced that data from ... of pain associated with painful diabetic neuropathy (PDN) will ... medical meetings.  The first poster will be presented at ...
... PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Healthcare Conference in Boston, MA.  James Winschel, Sr. Vice President ... PAREXEL at 2:00 p.m. ET on Wednesday, June 22, 2011. ... available through the "Investors" section of PAREXEL,s website ...
... 2011 /PRNewswire-Asia/ -- TWi Biotechnology Inc. announced today ... the total 240 patients for the Phase IIb ... Type II Diabetes. The randomized, double-blind, placebo-controlled, dose-ranging, ... glycated hemoglglobin A1c (HbA1c) lowering effects of AC-201 ...
Cached Biology Technology:Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 2Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 3PAREXEL International to Present at Wells Fargo Healthcare Conference 2Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes 2
(Date:12/22/2014)... 2014  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES ... Apollo Robbins will be at the ... demonstrating some of his famous theft techniques to visiting ...
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014 /PRNewswire/ ... the publication of a study that pinpoints fine-scale differences ... the United States . Since immigrants ... the United States has served as ... study illuminates how American history and the ongoing mixing ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... out at the University of Gothenburg may lead to more ... resistant plants, and crops with a limited absorption and storage ... organs in the human body, it is used in the ... active component of drugs against parasitic diseases. Healing ...
... 25, 2012The tiniest and the heaviest fetuses are at much ... new research has found. , Fetuses who are "severely small ... of all fetuses, disproportionately account for about six per cent ... , Fetuses that are "severely large for gestational age," or ...
... The human gut is home to a teeming ecosystem ... and disease. But while the gut microbiota is interacting ... viruses. In a study published online in ... system, revealing a common set of viruses associated with gut ...
Cached Biology News:Arsenic for better drugs and cleaner crops 2Smallest and largest fetuses at greater risk of being stillborn, research finds 2Gut microbes battle a common set of viruses shared by global populations 2
Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
... array sample elements. , , ,Includes: , , ... in PBS (10X): 50 ml , Streptavidin ... 8 packs , 10% Tween-20: 2 x 10 ... x 25 ml , SuperSignal West Pico Stable Peroxide: ...
... polyclonal antibody raised against a ... Immunogen: XAGE2 (NP_570133, ... partial recombinant protein with GST ... Number: NM_130777 ...
...
Biology Products: